Pirfenidone Advisory Committee Likely To Hinge On Clinical Meaningfulness Of FVC Test
This article was originally published in The Pink Sheet Daily
Executive Summary
InterMune's case is complicated by fact that statistical significance was met in only one of two pivotal trials.
You may also be interested in...
Pirfenidone Panel Highlights Difficulty Of Selecting Primary Endpoint In IPF
Though InterMune's pirfenidone still has the challenge of getting FDA approval based on mixed Phase III data using a not-yet validated primary endpoint, other drugs for idiopathic pulmonary fibrosis may face a clearer path to approvals following the Pulmonary-Allergy Drugs Advisory Committee March 9 review
Pirfenidone Panel Highlights Difficulty Of Selecting Primary Endpoint In IPF
Though InterMune's pirfenidone still has the challenge of getting FDA approval based on mixed Phase III data using a not-yet validated primary endpoint, other drugs for idiopathic pulmonary fibrosis may face a clearer path to approvals following the Pulmonary-Allergy Drugs Advisory Committee March 9 review
Despite Mixed Views On Efficacy Data, Advisory Committee Recommends Approval Of InterMune's Pirfenidone
InterMune's pirfenidone has a May 4 PDUFA date and would be the first drug approved for idiopathic pulmonary fibrosis.